关于推动全球抗疫医疗产品贸易谈判的初步研究  

A Preliminary Study on Launching the Global Trade Negotiation of Medical Products Relating to Tackle the COVID-19

作　　者：徐清军[1] 高波 XU Qingjun;GAO Bo

机构地区：[1]上海WTO事务咨询中心 [2]伦敦布鲁奈尔大学商学院,UB83PH

出　　处：《国际贸易问题》2020年第6期26-38,共13页Journal of International Trade

摘　　要：新冠肺炎疫情给国际贸易带来了冲击,口罩、呼吸机等必要医疗产品出现短缺和贸易限制现象。本文认为我国可以主动开展全球抗疫医疗产品贸易谈判。本文回顾了抗疫医疗产品谈判的前期工作,提出了抗疫医疗产品谈判范围,分析了抗疫医疗产品关税和成员分布情况,客观评估了我国参与抗疫医疗产品贸易谈判的利弊。在此基础上,提出了全球抗疫医疗产品贸易谈判的基本路径,包括制定全球抗疫医疗产品贸易便利化行为准则、探讨开展《医药产品贸易协定》扩围谈判、启动全球抗疫医疗产品开放式诸边谈判等。对于中国来说,全球抗疫医疗产品谈判成果的最终归途应是多边化,即纳入世贸组织规则框架。The COVID-19 pandemic brought impacts on international trade,and there are shortages and trade restrictions on the essential medical products such as facial masks and respirators to combat the pandemic.This paper notices that China may launch the global trade negotiations of medical products based on the internal-external conditions and massive demands for the medical products fighting against the pandemic,G20 leaders virtual meeting to call for trade policy initiatives,enriching new contents of WTO reform and the preliminary techniques based on Trade in Pharmaceutical Products and ITA-2.For this reason,this paper reviews the previous related works,puts forward the scope of negotiation,analyses the situation of tariff levels among WTO members,and evaluates the advantages and challenges of China’s participation in trade negotiation.Furthermore,this paper also proposes the feasible paths of trade negotiation,including formulating the code of conduct for trade facilitation of medical products,expanding the current scope of Trade in Pharmaceutical Products,and launching the open-plurilateral negotiations.For China,it is the best choice for pursuing the multilateralization of negotiation results which could be finalized this trade negotiation into WTO rulebooks.

关 键 词：新冠肺炎疫情 抗疫医疗产品 世贸组织改革 贸易谈判 

分 类 号：F741[经济管理—国际贸易]